Elaine S Jaffe1, Binita S Ashar2, Mark W Clemens3, Andrew L Feldman4, Philippe Gaulard5, Roberto N Miranda6, Aliyah R Sohani7, Timothy Stenzel8, Sung W Yoon2. 1. Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD. 2. Office of Surgical and Infection Control Devices, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD. 3. Department of Plastic Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN. 5. Department of Pathology, Hôpital Henri Mondor, Institut National de la Santé et de la Recherche Médicale U955, Université Paris-Est, Créteil, France. 6. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 7. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 8. Office of In Vitro Diagnostics and Radiological Health, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD.
Abstract
PURPOSE: To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulectomy specimen. METHODS: To better inform patients and healthcare providers about BIA-ALCL, we convened to review diagnostic procedures used in the evaluation of patients with suspected BIA-ALCL. We focused on the processing of the seroma fluid/effusion surrounding the implant, the handling of capsulectomy specimens following removal of implant(s), and the preoperative evaluation of the patient with suspected BIA-ALCL. Recommendations were based on the published literature and our experience to optimize procedures to obtain an accurate diagnosis and assess for tumor invasion and the extent of the disease. RECOMMENDATIONS: Early diagnosis of BIA-ALCL is important as the disease can progress and deaths have been reported. Because the most common presentation of BIA-ALCL is swelling of the breast with fluid collection, an accurate diagnosis requires cytologic evaluation of the effusion fluid surrounding the affected implant. The first priority is cytocentrifugation and filtration of fresh, unfixed effusion fluid to produce air-dried smears that are stained with Wright-Giemsa or other Romanowsky-type stains. Preparation of a cell block is desirable to allow for hematoxylin and eosin staining and immunohistochemical analysis of formalin-fixed, paraffin-embedded histologic sections. Cell block sections can be used for polymerase chain reaction-based investigation of T-cell receptor gene rearrangement to detect clonality. Fixation and mapping of the capsulectomy specimen to select multiple representative sections are advised to assess for microscopic tumor involvement and capsular invasion. It is appropriate to assess lymph node involvement by excisional biopsy material rather than fine needle aspiration, due to propensity for focal involvement.
PURPOSE: To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulectomy specimen. METHODS: To better inform patients and healthcare providers about BIA-ALCL, we convened to review diagnostic procedures used in the evaluation of patients with suspected BIA-ALCL. We focused on the processing of the seroma fluid/effusion surrounding the implant, the handling of capsulectomy specimens following removal of implant(s), and the preoperative evaluation of the patient with suspected BIA-ALCL. Recommendations were based on the published literature and our experience to optimize procedures to obtain an accurate diagnosis and assess for tumor invasion and the extent of the disease. RECOMMENDATIONS: Early diagnosis of BIA-ALCL is important as the disease can progress and deaths have been reported. Because the most common presentation of BIA-ALCL is swelling of the breast with fluid collection, an accurate diagnosis requires cytologic evaluation of the effusion fluid surrounding the affected implant. The first priority is cytocentrifugation and filtration of fresh, unfixed effusion fluid to produce air-dried smears that are stained with Wright-Giemsa or other Romanowsky-type stains. Preparation of a cell block is desirable to allow for hematoxylin and eosin staining and immunohistochemical analysis of formalin-fixed, paraffin-embedded histologic sections. Cell block sections can be used for polymerase chain reaction-based investigation of T-cell receptor gene rearrangement to detect clonality. Fixation and mapping of the capsulectomy specimen to select multiple representative sections are advised to assess for microscopic tumor involvement and capsular invasion. It is appropriate to assess lymph node involvement by excisional biopsy material rather than fine needle aspiration, due to propensity for focal involvement.
Authors: William E Katzin; José A Centeno; Lu-Jean Feng; Maureen Kiley; Florabel G Mullick Journal: Am J Surg Pathol Date: 2005-04 Impact factor: 6.394
Authors: Matthew J Carty; Julian J Pribaz; Joseph H Antin; Elgida R Volpicelli; Christiana E Toomey; Evan A Farkash; Ephraim P Hochberg Journal: Plast Reconstr Surg Date: 2011-09 Impact factor: 4.730
Authors: José Mendes; Vinicius A Mendes Maykeh; Luiz Fernando Frascino; Flavia F S Zacchi Journal: Plast Reconstr Surg Date: 2019-09 Impact factor: 4.730
Authors: Babette E Becherer; Mintsje de Boer; Pauline E R Spronk; Annette H Bruggink; Jan Paul de Boer; Flora E van Leeuwen; Marc A M Mureau; René R J W van der Hulst; Daphne de Jong; Hinne A Rakhorst Journal: Plast Reconstr Surg Date: 2019-05 Impact factor: 4.730
Authors: Colleen M McCarthy; Nilsa Loyo-Berríos; Ali A Qureshi; Erin Mullen; Gayle Gordillo; Andrea L Pusic; Binita S Ashar; Katie Sommers; Mark W Clemens Journal: Plast Reconstr Surg Date: 2019-03 Impact factor: 4.730
Authors: Roberto N Miranda; L Jeffrey Medeiros; Maria C Ferrufino-Schmidt; John A Keech; Garry S Brody; Daphne de Jong; Ahmet Dogan; Mark W Clemens Journal: Plast Reconstr Surg Date: 2019-03 Impact factor: 4.730
Authors: Garry S Brody; Dennis Deapen; Clive R Taylor; Lauren Pinter-Brown; Sarah Rose House-Lightner; James S Andersen; Grant Carlson; Melissa G Lechner; Alan L Epstein Journal: Plast Reconstr Surg Date: 2015-03 Impact factor: 4.730
Authors: Rosario Granados; Eva M Lumbreras; Manuel Delgado; José A Aramburu; Juan C Tardío Journal: Diagn Cytopathol Date: 2016-04-15 Impact factor: 1.582
Authors: Piers Blombery; Ella Thompson; Georgina L Ryland; Rachel Joyce; David J Byrne; Christine Khoo; Stephen Lade; Mark Hertzberg; Greg Hapgood; Paula Marlton; Anand Deva; Geoffrey Lindeman; Stephen Fox; David Westerman; Miles Prince Journal: Oncotarget Date: 2018-11-16
Authors: Elaine S Jaffe; Andrew L Feldman; Philippe Gaulard; Roberto N Miranda; Aliyah R Sohani Journal: J Clin Oncol Date: 2020-06-17 Impact factor: 44.544
Authors: Carlos Andres Ossa Gomez; Jose Fernando Robledo Abad; Alejandro Duque; Ramiro Huertas; Ana Maria Fidalgo; Giovanna Rivas Taffur; Jose Joaquin Caicedo Mallarino; Fabio Torres; William Armando Mantilla Duran; Virginia Abello; Roberto N Miranda; Carolina Echeverri; Mark Warren Clemens Journal: Plast Reconstr Surg Glob Open Date: 2020-08-18
Authors: Andrés E Quesada; Yanming Zhang; Ryan Ptashkin; Caleb Ho; Steven Horwitz; Ryma Benayed; Ahmet Dogan; Maria E Arcila Journal: Breast J Date: 2021-02-18 Impact factor: 2.431
Authors: Anand K Deva; Suzanne D Turner; Marshall E Kadin; Mark R Magnusson; H Miles Prince; Roberto N Miranda; Giorgio G Inghirami; William P Adams Journal: Cancers (Basel) Date: 2020-12-21 Impact factor: 6.639